Breast effects of bazedoxifene-conjugated estrogens: A Randomized Controlled Trial

Obstetrics and Gynecology

Volumn 121, Issue 5, 2013, Pages 959-968

  Pinkerton, JoAnn V ^a   Harvey, Jennifer A ^a   Pan, Kaijie ^a   Thompson, John R ^a   Ryan, Kelly A ^a   Chines, Arkadi A ^a   Mirkin, Sebastian ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAZEDOXIFENE; BAZEDOXIFENE CONJUGATED ESTROGEN; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; BREAST; BREAST DISEASE; BREAST TENDERNESS; COMPUTER PROGRAM; CONFERENCE PAPER; CONTROLLED STUDY; DIGITAL MAMMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VASOMOTOR DISORDER;

BREAST; DOUBLE-BLIND METHOD; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; INDOLES; MAMMOGRAPHY; MIDDLE AGED; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84879078406     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31828c5974     Document Type: Conference Paper

References (39)

1. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ, et al. Mammographic breast density as an intermediate pheno-type for breast cancer. Lancet Oncol 2005; 6: 798-808.
2. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 2010; 102: 1224-37.
3. Heusinger K, Loehberg CR, Haeberle L, Jud SM, Klingsiek P, Hein A, et al. Mammographic density as a risk factor for breast cancer in a German case-control study. Eur J Cancer Prev 2011; 20: 1-8.
4. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-69.
5. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003; 12: 332-8.
6. Varghese JS, Thompson DJ, Michailidou K, Lindstrom S, Turnbull C, Brown J, et al. Mammographic breast density and breast cancer: evidence of a shared genetic basis. Cancer Res 2012; 72: 1478-84.
7. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92: 1081-7.
8. Pinsky RW, Helvie MA. Mammographic breast density: effect on imaging and breast cancer risk. J Natl Compr Canc Netw 2010; 8: 1157-64.
9. Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res 2006; 32: 305-8.
10. Kaewrudee S, Anuwutnavin S, Kanpittaya J, Soontrapa S, Sakondhavat C. Effect of estrogen-progestin and estrogen on mammographic density. J Reprod Med 2007; 52: 513-20.
11. McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005; 97: 1366-76.
12. Rossouw JE, Anderson GL, Prentice RL, La Croix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
13. Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006; 55: 103-15.
14. Boyd NF, Melnichouk O, Martin LJ, Hislop G, Chiarelli AM, Yaffe MJ, et al. Mammographic density, response to hormones, and breast cancer risk. J Clin Oncol 2011; 29: 2985-92.
15. Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy? J Womens Health Gend Based Med 2001; 10: 343-50.
16. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson G, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat 2012; 132: 275-85.
17. Crandall CJ, Aragaki AK, Cauley JA, McTiernan A, Manson JE, Anderson GL, et al. Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat 2012; 131: 969-79.
18. Komm BS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci 2008; 15: 984-92.
19. Lobo RA, Pinkerton JV, Gass ML, Dorin MH, Ronkin S, Pickar JH, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009; 92: 1025-38.
20. Pinkerton JV, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009; 16: 1116-24.
21. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010; 17: 281-9.
22. Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk post-menopausal women. Fertil Steril 2009; 92: 1045-52.
23. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009; 92: 1039-44.
24. Pickar JH, Yeh I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing baze-doxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009; 92: 1018-24.
25. Pinkerton JV, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause 2010; 17: 1221-2.
26. Pinkerton JA, Constantine GD, Komm BS, Yu H, Pickar JH. Breast effects of bazedoxifene/conjugated estrogens in a randomized, controlled trial of postmenopausal women. Menopause 2008; 15: 1221.
27. Harvey JA, Pinkerton JV, Baracat EC, Shi H, Mirkin S, Chines AA. Evaluation of changes in mammographic breast density associated with bazedoxifene/conjugated estrogens in postmenopausal women. Endocr Rev 2011; 32.
28. American College of Radiology. Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston (VA): American College of Radiology; 2003.
29. Byng JW, Yaffe MJ, Jong RA, Shumak RS, Lockwood GA, Tritchler DL, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998; 18: 1587-98.
30. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-92.
31. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in post-menopausal women with hysterectomy. JAMA 2006; 295: 1647-57.
32. La Croix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011; 305: 1305-14.
33. Christiansen C, Chesnut CH III, Adachi JD, Brown JP, Fernandes CE, Kung AW, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010; 11: 130.
34. de Villiers TJ, Chines AA, Palacios S, Lips P, Sawicki AZ, Levine AB, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-76.
35. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001; 949: 317-26.
36. Komm BS, Kharode YP, Bodine PV, Harris HA, Miller CP, Lyttle CR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005; 146: 3999-4008.
37. Peano BJ, Crabtree JS, Komm BS, Winneker RC, Harris HA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009; 150: 1897-903.
38. Chang KCN, Wang Y, Bodine PV, Nagpal S, Komm BS. Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010; 118: 117-24.
39. Archer DF, Lobo RA, Pan K, Chines AA, Mirkin S. Safety and tolerability of bazedoxifene/conjugated estrogens in postmeno-pausal women: findings from a 1-year, randomized, placeboand active-controlled, phase 3 trial. Menopause 2011; 18: 1355-6.